Your browser doesn't support javascript.
loading
Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK).
Hevener, Kirk E; Santarsiero, Bernard D; Lee, Hyun; Jones, Jesse A; Boci, Teuta; Johnson, Michael E; Mehboob, Shahila.
Afiliación
  • Hevener KE; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Suite 571, Memphis, TN 38163-2198, USA.
  • Santarsiero BD; Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
  • Lee H; Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
  • Jones JA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Suite 571, Memphis, TN 38163-2198, USA.
  • Boci T; Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
  • Johnson ME; Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
  • Mehboob S; Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 South Ashland Avenue, Suite 3100, Chicago, IL 60607-7173, USA.
Acta Crystallogr F Struct Biol Commun ; 74(Pt 2): 105-112, 2018 02 01.
Article en En | MEDLINE | ID: mdl-29400320
ABSTRACT
Enoyl-acyl carrier protein (ACP) reductase II (FabK) is a critical rate-limiting enzyme in the bacterial type II fatty-acid synthesis (FAS II) pathway. FAS II pathway enzymes are markedly disparate from their mammalian analogs in the FAS I pathway in both structure and mechanism. Enzymes involved in bacterial fatty-acid synthesis represent viable drug targets for Gram-negative pathogens, and historical precedent exists for targeting them in the treatment of diseases of the oral cavity. The Gram-negative organism Porphyromonas gingivalis represents a key causative agent of the costly and highly prevalent disease known as chronic periodontitis, and exclusively expresses FabK as its enoyl reductase enzyme in the FAS-II pathway. Together, these characteristics distinguish P. gingivalis FabK (PgFabK) as an attractive and novel narrow-spectrum antibacterial target candidate. PgFabK is a flavoenzyme that is dependent on FMN and NADPH as cofactors for the enzymatic reaction, which reduces the enoyl substrate via a ping-pong mechanism. Here, the structure of the PgFabK enzyme as determined using X-ray crystallography is reported to 1.9 Šresolution with endogenous FMN fully resolved and the NADPH cofactor partially resolved. PgFabK possesses a TIM-barrel motif, and all flexible loops are visible. The determined structure has allowed insight into the structural basis for the NADPH dependence observed in PgFabK and the role of a monovalent cation that has been observed in previous studies to be stringently required for FabK activity. The PgFabK structure and the insights gleaned from its analysis will facilitate structure-based drug-discovery efforts towards the prevention and treatment of P. gingivalis infection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Porphyromonas gingivalis / Enoil-ACP Reductasa (NADH) Límite: Humans Idioma: En Revista: Acta Crystallogr F Struct Biol Commun Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Porphyromonas gingivalis / Enoil-ACP Reductasa (NADH) Límite: Humans Idioma: En Revista: Acta Crystallogr F Struct Biol Commun Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos